Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.45 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1397268 | 1.00 | CYSLTR2 (0.45) | CYSLTR2CYSLTR1 | |
| SCHEMBL12856340 | 0.98 | CYSLTR2 (0.45) | CYSLTR2CYSLTR1 | |
| SCHEMBL14620846 | 0.89 | CYSLTR2 (0.44) | CYSLTR2CYSLTR1 | |
| SCHEMBL12267469 | 0.89 | CYSLTR2 (0.49) | CYSLTR2CYSLTR1 | |
| SCHEMBL18192997 | 0.87 | CYSLTR2 (0.46) | CYSLTR2CYSLTR1 | |
| SCHEMBL14527479 | 0.85 | CYSLTR1 (0.49) | CYSLTR2CYSLTR1 | |
| SCHEMBL18192993 | 0.85 | CYSLTR2 (0.48) | CYSLTR2CYSLTR1 | |
| SCHEMBL14527588 | 0.84 | — | — | |
| SCHEMBL10224774 | 0.84 | CYSLTR1 (0.49) | CYSLTR2CYSLTR1 | |
| SCHEMBL12597691 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009144742-A3 | AN IMPROVED PROCESS FOR PREPARING MONTELUKAST AND SALTS THEREOF | APTUIT LAURUS PVT LIMITED (IN) | 2014-09-04 | — | — | WO | disclosed |
| US-8367834-B2 | Process for preparing Montelukast and salts thereof | LAURUS LABS PRIVATE LIMITED (IN) | 2013-02-05 | — | — | US | disclosed |
| US-20110112300-A1 | IMPROVED PROCESS FOR PREPARING MONTELUKAST AND SALTS THEREOF | Aptuit Laurus Pvt. Ltd. (IN) | 2011-05-12 | — | — | US | disclosed |
| EP-2288595-A2 | AN IMPROVED PROCESS FOR PREPARING MONTELUKAST AND SALTS THEREOF | Aptuit Laurus Pvt Limited (IN) | 2011-03-02 | — | — | EP | disclosed |
| WO-2009144742-A2 | AN IMPROVED PROCESS FOR PREPARING MONTELUKAST AND SALTS THEREOF | APTUIT LAURUS PVT LIMITED (IN) | 2009-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112300-A1 | IMPROVED PROCESS FOR PREPARING MONTELUKAST AND SALTS THEREOF | MPST, TST, CMA1 | CYSLTR2 14/4885CYSLTR1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.